Editorial
Published on 30 Jul 2024
Editorial: Pharmacoinformatics: new developments and challenges in drug design
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1462070
- 701 views
Type at least 3 characters
921 articles
Articles
Original Research
Published on 30 Jul 2024
The 5HT4R agonist velusetrag efficacy on neuropathic chronic intestinal pseudo-obstruction in PrP-SCA7-92Q transgenic mice
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1411642
- 902 views
Original Research
Published on 30 Jul 2024
Nanoparticles (NPs)-mediated lncMALAT1 silencing to reverse cisplatin resistance for effective hepatocellular carcinoma therapy
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1437071
- 1,078 views
Original Research
Published on 29 Jul 2024
Causal gene identification using mitochondria-associated genome-wide mendelian randomization in atrial fibrillation
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1439816
- 1,457 views
Original Research
Published on 25 Jul 2024
When to consider intra-target microdosing: physiologically based pharmacokinetic modeling approach to quantitatively identify key factors for observing target engagement
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1366160
- 1,016 views
Review
Published on 25 Jul 2024
Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1417399
- 1,414 views
- 1 citation
Review
Published on 25 Jul 2024
Bibliometric and visualized analysis of ultrasound combined with microbubble therapy technology from 2009 to 2023
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1418142
- 1,099 views
Original Research
Published on 22 Jul 2024
Pan-cancer analyses reveal the molecular and clinical characteristics of TET family members and suggests that TET3 maybe a potential therapeutic target
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1418456
- 1,166 views
Review
Published on 18 Jul 2024
Bibliometric analysis of vitamin D and obesity research over the period 2000 to 2023
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1445061
- 1,534 views
Original Research
Published on 18 Jul 2024
Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1433147
- 2,372 views
Editorial
Published on 16 Jul 2024
Editorial: Incorporating Phase 0 microdosing as a powerful tool into a new vision of drug development
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1455643
- 565 views
Clinical Trial
Published on 15 Jul 2024
A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1400696
- 2,650 views
- 1 citation
Original Research
Published on 10 Jul 2024
Repurposing the Open Global Health Library for the discovery of novel Mpro destabilizers with scope as broad-spectrum antivirals
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1390705
- 787 views
Original Research
Published on 03 Jul 2024
Individualized, dynamic, and full-course vancomycin dosing prediction: a study on the customized dose model
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1414347
- 779 views
Opinion
Published on 02 Jul 2024
Life scientists improve QSP model quality and impact
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1392747
- 741 views
Case Report
Published on 27 Jun 2024
Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin’s lymphoma being treated for invasive pulmonary aspergillosis
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2024.1403966
- 934 views
- 1 citation